Last fall some people in the know about influenza science got picky when it came time to get their flu shots.

They didn’t want to roll up their sleeve for any old vaccine on offer at their doctor’s office or workplace clinic. They sought specific products, the ones licensed for older adults that contain a performance-boosting compound called an adjuvant or more notably one of the two brands of vaccine not made — as most flu vaccines are — in eggs.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Imagine the reaction of the public — and the media — and STAT (looking at you Ed) — if an arm of the Fed issued guidance that favored one flu vaccine formulation over another. Big government is in cahoots with big pharma!!! OMG!!!
    Then the price of the version with only 300K doses produced shoots up. More outrage.
    Seriously, this is why FDA for decades has gone out of its way to be very conservative about allowing any competitive study data into a drug’s Prescribing Information. There’s no way CDC or whoever is going on the record saying one brand is better than another without iron clad data.
    To know enough to be able to make an informed decision based on nuanced understanding for one kind of flu vaccine over another is an insider thing. Get to know, or be lucky enough to be related, to one of these insiders. Or dive in and immerse yourself in this topic. But the gov’t ain’t coming to save you on this — which is the way we should all want it.

  • Guidance to the public is scant. Most individuals do not refer to the CDC regularly, if at all. Public health departments must have funding for education so why are they not following that mandate? Perhaps it’s time for CDC, or Health & Human Services to participate in TV “infomercials” to educate the public on out how to avoid becoming ill with the Flu in the first place. Also offered should be advice on what vaccine is best for each age group. Move over Big Pharma!

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy